DeepQure Reports the US FDA’s IDE Approval of HyperQure for Treating Resistant Hypertension
Shots:
- DeepQure has received the US FDA’s IDE approval to conduct an Early Feasibility Study (EFS) assessing the safety & efficacy of HyperQure in individuals (n=15) with resistant hypertension across various sites in the US
- The system’s FIH ongoing Korean study depicted symptomatic improvements in patients having uncontrolled hypertension even after 5-8 hypertensive drugs. The RDN treatment utilizing HyperQure reduced blood pressure without any AEs
- HyperQure system, comprising an energy generator & a laparoscopic instrument, uses RF energy to ablate sympathetic nerves around the renal artery by wrapping it 360 degrees externally, allowing full denervation without affecting the vascular endothelium
Ref: PR Newswire | Image: DeepQure
Related News:- Innovent Reports the NMPA’s NDA Acceptance of IBI311 for Treating Thyroid Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
